Gerry C. Bohac
Amgen
7 Papers
7 Citations
Gerry C. Bohac is an academic researcher from Amgen. The author has contributed to research in topics: Medicine & Antibody-drug conjugate. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Sekwon Jang,John D. Powderly,Alexander I. Spira,Ouiam Bakkacha,Deryk T. Loo,Gerry C. Bohac,Manish Sharma +6 more
TL;DR: A phase 1 study characterizes safety, maximum tolerated or maximum administered dose, pharmacokinetics, immunogenicity, and tumor response per RECIST v1.1 of MGC018 in patients with advanced solid tumors, with early evidence of clinical activity in pretreated metastatic melanoma.
29
Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).
Neeta Somaiah,Sant P. Chawla,Matthew S. Block,John C. Morris,Khanh Tu Do,Joseph Kim,Mihaela Druta,Kamalesh Kumar Sankhala,Patrick Hwu,Sacha Gnjatic,Hailing Lu,Richard T. Kenney,Gerry C. Bohac,Seth M. Pollack +13 more
TL;DR: CMB305 is an active immunotherapy regimen designed to generate and expand anti-NY-ESO-1 T cells that consists of LV305, a dendritic cell targeting lentiviral vector encoding NY-ESo-1 encoding T cells.
21
Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
TL;DR: This data indicates that continued treatment with a prophylactic administration of ADCs for at least three months after vaccination with a monoclonal antibody halves the chance of adverse events.
19
Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.
Seth M. Pollack,Hailing Lu,Neeta Somaiah,Sant P. Chawla,John C. Morris,Khanh Tu Do,Joseph Kim,Matthew S. Block,Marissa Vignali,Julie A. Rytlewski,Erik Yusko,Frank J. Hsu,Gerry C. Bohac,Sacha Gnjatic,Jan ter Meulen +14 more
TL;DR: Relationship between progression-free survival (PFS), overall survival (OS) and up to 15 biomarkers were analyzed and the correlation of immune response (IR) and clinical benefit in patients (pts) who receive active immunotherapy remains controversial.
5
Survival effects of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer: A meta-analysis.
Brian Leyland-Jones,Matti Aapro,Volker Moebus,Ulrike Nitz,Joyce O'Shaughnessy,Paolo Pronzato,Michael Untch,Dianne Tomita,Gerry C. Bohac +8 more
TL;DR: A meta-analysis of trials of ESA use in patients with breast cancer receiving chemotherapy found overall survival OR remains consistent with prior data after including recent results.
1